Identification of twelve new susceptibility loci for different histotypes of epithelial ovarian cancer

Supplementary Note

Australian Ovarian Cancer Study (AOCS) Group


Ovarian Cancer Prognosis and Lifestyle (OPAL) Group

A. Obermair, M. Friedlander, P. Grant

The EMBRACE study collaborators


The Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study collaborators

Olga Sinilnikova†, Sylvie Mazoyer, Francesca Damiola, Laure Barjhoux, Carole Verny-Pierre, Mélanie Léone, Nadia Boutry-Kryza, Alain Calender, Sophie Giraud, Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude Houdayer, Etienne Rouleau, Lisa Golmard, Agnès Collet, Virginie Moncoutier, Muriel Belotti, Antoine de Pauw, Camille Elan, Catherine Nogues, Emmanuelle Fourme, Anne-Marie Birot, Brigitte Bressac-de-Pailerets, Olivier Caron, Marine
Identification of twelve new susceptibility loci for different histotypes of epithelial ovarian cancer


The HEBON study collaborators


Kathleen Cunningham Foundation Consortium for research into Familial Breast cancer (kCONFAB)

Morteza Aghmesheh, David Amor, Lesley Andrews, Yolanda Antill, Shane Armitage, Leanne Arnold, Rosemary Balleine, Agnes Bankier, Patti Bastick, John Beilby, Barbara Bennett, Ian Bennett, Geoffrey Berry, Anneke Blackburn, Michael Bogwitz, Meagan Brennan, Melissa Brown, Michael Buckley, Matthew Burgess, Jo Burke, Phyllis Butow, Keith Byron, David Callen, Ian Campbell, Deepa Chauhan, Manisha Chauhan, Alice Christian, Christine Clarke, Alison Colley, Dick Cotton, Ashley Crook, James Cui, Bronwyn Culling, Margaret Cummings, Sarah-Jane Dawson, Martin Delatycki, Rebecca Dickson, Joanne Dixon, Alexander Dobrovic, Tracy Dudding, Ted Edkins, Stacey Edwards, Maurice Eisenbruch, Gelareh Farshid, Susan Fawcett, Andrew Fellows, Georgina Fenton, Michael Field, Frank Frgaira, James Flanagan, Jean Fleming, Peter Fong, John Forbes, Stephen Fox, Juliet French, Michael Friedlander, Clara Gaff, Mac Gardner, Mike Gattas, Peter George, Graham Giles, Grantley Gill, Jack Goldblatt, Sian Greening, Scott Grist, Eric Haan, Kate Hardie, Marion Harris, Stewart Hart, Nick Hayward, Sue Healey, Louise Heiniger, John Hopper, Evelyn Humphrey, Clare Hunt, Paul James, Mark Jenkins, Alison Jones, Rick Kefferd, Alexa Kidd, Belinda Kiely, Judy Kirk, Jessica Koehler, James Kollias, Serguei Kovalenko, Sunil Lakhani, Amanda Leaming, Jennifer Leary, Jacqueline Lim, Geoff Lindeman, Lara Lipton, Liz Lobb, Graham Mann, Deborah Marsh, Sue Anne McLachlan, Bettina Meiser, Cliff Meldrum, Roger Milne, Gillian Mitchell, Beth Newman, Sophie Nightingale, Shona O’Connell, Imelda O’Loughlin, Richard Osborne, Nick Pachter, Briony Patterson, Lester Peters, Kelly Phillips, Melanie Price, Lynne Purser, Tony Reeve, Jeanne Reeve, Robert Richards, Edwina Rickard, Bridget Robinson, Barney Rudzki, Mona Saleh, Elizabeth Salisbury, Joe Sambbrook, Christobel Saunders, Jodi Saunus, Robyn Sayer, Elizabeth Scott, Rodney Scott, Clare Scott, Ram Seshadri, Adrienne Sexton, Raghwa Sharma, Andrew Sheiling, Peter Simpson, Melissa Southey, Amanda Spurdle, Graeme Suthers, Pamela Sykes, Donna Taylor, Jessica Taylor, Benjamin Thierry, Susan Thomas, Ella Thompson,
Identification of twelve new susceptibility loci for different histotypes of epithelial ovarian cancer

Heather Thorne, Sharron Townshend, Alison Trainer, Lan Tran, Kathy Tucker, Janet Tyler, Jane Visvader, Logan Walker, Ian Walpole, Robin Ward, Paul Waring, Bev Warner, Graham Warren, Rachael Williams, Judy Wilson, Ingrid Winship, Kathy Wu, Mary Ann Young.

OCAC Acknowledgements

We thank study participants, doctors, nurses, clinical and scientific collaborators, health care providers and health information sources who have contributed to the participating studies. This study would not have been possible without the contributions of the following: J Dennis, A. M. Dunning, D. F. Easton, P. Hall (COGS); D. C. Tessier, F. Bacot, D. Vincent, S. LaBoissière and F. Robidoux and the staff of the genotyping unit, (Genome Quebec); G. Peuteman, T. Van Brussel and D. Smeeets (BEL); U. Eilber and T. Koehler (GER); L. Gacucova (HMO); P. Schürmann, F. Kramer, W. Zheng, T.-W. Park-Simon, K. Beer-Grondke and D. Schmidt (HJO); G.S. Keeney, S. Windebank, C. Hilker and J. Vollenweider (MAY); the US state cancer registries of AL, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WYL (NHS); L. Paddock, M. King, U. Chandran, A. Samoila, and Y. Bensman (NJO); L. Brinton, M. Sherman, A. Hutchinson, N. Szieszienia-Dabrowska, B. Peplonska, W. Zatonski, A. Soni, P. Chao and M. Stagner (POL); C. Luccarini, P. Harrington, C. Baynes and D. Conroy the SEARCH team and ECRIC (SEA); the Scottish Gynaecological Clinical Trials group and SCOTROC1 investigators (SRO); W.-H. Chow, Y.-T. Gao (SWH); Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov/ (TCGA); I. Jacobs, M. Widschwendter, E. Wozniak, N. Balogun, A. Ryan and J. Ford (UKO); Carole Pye (UKR); a full list of the investigators who contributed to the generation of the WTCCC data is available from http://www.wtccc.org.uk/ (WTCCC).

OCAC funding

The COGS project was funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175). The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium. Funding for the project was provided by the Wellcome Trust under award 076113. The results published here are in part based upon data generated by The Cancer Genome Atlas Pilot Project established by the National Cancer Institute and National Human Genome Research Institute (dbGap accession number phs000178.v8.p7).

Funding for individual studies is listed below.

AAS: NIH (R01-CA14208)
BAV: ELAN Funds of the University of Erlangen-Nuremberg
BEL: Nationaal Kankerplan
BGS: National Institutes of Health Biomedical Research Centreat the Institute of Cancer Research
Identification of twelve new susceptibility loci for different histotypes of epithelial ovarian cancer

Supplementary Note

BVU: NIH (ULTR000445);
CNI: Instituto de Salud Carlos III (PI 12/01319); Ministerio de Economía y Competitividad (SAF2012-35779)
DKE: Ovarian Cancer Research Fund
DOV: NIH (R01-CA112523, R01-CA087538)
EPIC: the European Commission, DG-SANCO and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society; Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale; German Cancer Aid, German Cancer Research Center, Federal Ministry of Education and Research; the Hellenic Health Foundation; Associazione Italiana per la Ricerca sul Cancro and National Research Council; Dutch Ministry of Public Health, Welfare and Sports, Netherlands Cancer Registry, LK Research Funds, Dutch Prevention Funds, Dutch ZON, World Cancer Research Fund, Statistics Netherlands; ERC-2009-AdG 232997 and Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health; Health Research Fund (PI13/00061 and PI13/01162), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten; Cancer Research UK (14136 C570/A16491 and C8221/A19170), Medical Research Council (1000143, MR/M012190/1).
GER: German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401); the German Cancer Research Center.
GRC: European Union (European Social Fund; Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework Research Funding Program of the General Secretariat for Research & Technology (SYN11_10_19 NBCA)
GRR: NIH (P30-CA016056)
HAW: R01-CA058598, N01-CN-55424, N01-PC-67001 (HAW);
HOC: Helsinki University Research Fund
HJO/HMO/HUO: Rudolf-Bartling Foundation
HOP: NIH (K07-CA080668, R01-CA095023, P50-CA159981, MO1-RR000056), U.S. Department of Defense Congressionally Directed Medical Research Program (DAMD17-02-1-0669)
ICR: Breast Cancer Now, Institute of Cancer Research (ICR)
LAX: NIH (UL1TR000124)
LUN/SMC: Beta Kamprad Foundation; European Research Council (ERC-2011-AdG 294576); Swedish Cancer; Swedish Research Council
MAC/MAY: Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation; Fraternal Order of Eagles; NIH (R01-CA122443, P30-CA15083, P50-CA136393)
MAL: Danish Cancer Society (94 222 52); the Mermaid I project; NIH (R01- CA061107)
MCC: Cancer Council Victoria; National Health & Medical Research Council of Australia (209057, 251533, 396414 and 504715)
MDA: U.S. Department of Defense Congressionally Directed Medical Research Program (W81XWH-07-0449)
MEC: NIH (R01-CA054281, R01-CA164973, R01-CA063464)
MOF: NIH (R01-CA114343)
Identification of twelve new susceptibility loci for different histotypes of epithelial ovarian cancer

Supplementary Note

NCO: NIH (R01-CA076016); U.S. Department of Defense Congressionally Directed Medical Research Program (DAMD17-02-1-0666)

NEC: NIH (R01-CA054419, P50-CA105009); U.S. Department of Defense Congressionally Directed Medical Research Program (W81XWH-10-1-02802)

NHS: NIH (R01-CA067262, UM1 CA176726, UM1 CA186107, P01 CA087969, R01 CA049449)

NOR: Helse Vest; The Norwegian Cancer Society; The Research Council of Norway

NTH: Radboud University Medical Centre

ORE: OHSU Foundation

OVA: Canadian Institutes of Health Research grant (MOP-86727); NIH (R01CA160669)

POC: Pomeranian Medical University

POL: NIH (Intramural Research Program).

PV: Herlev Hospitals Forskningsråd, Direktør Jacob Madsens og Hustru Olga Madsens fond, Arvid Nilssons fond, Gangsted fonden, Herlev Hospitals Forskningsråd and Danish Cancer Society

RPC: NIH (P50 CA159981, R01CA126841); Roswell Park Cancer Institute Alliance Foundation

SEARCH: Cambridge NIHR Biomedical Research Centre and Cancer Research UK Cambridge Cancer Centre; Cancer Research UK (C490/A10119, C490/A10124)

SIS: NIH (Intramural Research Program, Z01 ES044005)

SMC: The Swedish Research Council

SRO: Cancer Research UK (C536/A13086, C536/A6689 and C1312/A15589)

STA: NIH (U01-CA071966, R01-CA016056, K07-CA143047, U01-CA069417)

TBO: Celma Mastery Ovarian Cancer Foundation ; NIH (R01-CA106414); American Cancer Society (CRTG-00-196-01-CCE); U.S. Department of Defense Congressionally Directed Medical Research Program (DAMD17-98-1-8659).

TOR: R01 CA063678, R01 CA063682 (TOR);

UCI: Lon V Smith Foundation LVS-39420; (R01-CA058860)

UHN: Princess Margaret Cancer Centre Foundation-Bridge for the Cure

UKO: The Eve Appeal, The Oak Foundation, and NIHR University College London Hospitals Biomedical Research Centre.

UKR: Cancer Research UK (C490/A6187)

USC: California Cancer Research Program (00-01389V-20170, 2II0200); NIH (P01CA17054, P30CA014089, R01CA061132, N01PC67010, R03CA113148, R03CA115195, N01CN025403)

VAN: BC Cancer Foundation, VGH & UBC Hospital Foundation (VAN).

WMH: Cancer Institute NSW (11/TRC/1-06 and 12/RIG/1-17); National Health & Medical Research Council of Australia (310670 and 628903).

WOC: National Science Centre (N N301 5645 40); The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

CIMBA Acknowledgements
We thank the following individuals: Sue Healey for her enormous contribution to CIMBA. Maggie Angelakos, Judi Maskiell, Gillian Dite, Helen Tsimiklis (BCFR-AU); Vilius Rudaitis and Laimonas Griškevičius (BFBOCC-LT); Drs. Janis Eglitis, Anna Krilova and Aivars Stengrevics (BFBOCC-LV); Yuan Chun Ding and Linda Steele (BRICOH); Alicia Barroso, Rosario Alonso and Guillermo Pita (CNIO); Ms. JoEllen Weaver and Dr. Betsy Bove (FCCC); Marta Santamariña, Ana Blanco, Miguel Aguado, Uxía Esperón and Belinda Rodríguez (FPGMX); Ilse Coene en Brecht Crombez (G-FAST); Alicia Tosar and Paula Diaque (HCSC); Drs. Kristiina Attomäki, Taru A. Muranen, Carl Blomqvist and Kirsimari Aaltonen and RNs Irja Erkkilä and Virpi Palola (HEBCS); Janos Papp, Tibor Vaszko, Aniko Bozsik, Judit Franko, Maria Balogh, Gabriella Domokos, Judit Ferenczi (HUNBOCS); ICO Hereditary Cancer Program team led by Dr. Gabriel Capella (ICO); Dr Martine Dumont, Martine Tranchant (INHERIT); Drs. Catarina Santos and Pedro Pinto (IPOBCS); Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (kConFab); Kevin Sweet, Leigha Senter, Julia Cooper and Michelle O’Conor (OSUCCG); Sara Dishon, Dr. Flavio Lejbkowicz and Dr. Mila Pinchev (NICCC National Familial Cancer Consultation Service team); Lenka Foretova, Eva Machackova, Michal Zikan, Petr Pohlreich and Zdenek Kleibl (MODSQUAD); Yip Cheng Har, Nur Aishah Mohd Taib, Phuah Sze Yee, Norhashimah Hassan; Philip Iau, Sng Jen-Hwei (Singapore Breast Cancer Study) and Sharifah Nor Akmal (HUKM-HKL) (SEABBAS); Helena Jernström, Karin Henriksson, Katja Harbst, Maria Soller, Ulf Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Anna Överholm, Margareta Nordling, Per Karlsson, Zakaria Einbeigi; from Stockholm and Karolinska University Hospital: Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Gisela Barbany Bustinza, Johanna Rantala; from Umeå University Hospital: Beatrice Melin, Christina Edwinsdotter Arndor, Monica Emanuelsson; from Uppsala University: Hans Ehrencreuna, Maritta Hellström Pigg, Richard Rosenquist; from Linköping University Hospital: Marie Stenmark-Askmalm, Sigrun Liedgren (UCLA); Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Blanco, Peggy Conrad (UCSF); Carole Pye and Eva Wozniak (UKFOCR); Anne Lincoln, Lauren Jacobs (MSKCC); Geoffrey Lindeman, Marion Harris, Martin Delatycki, Sarah Sawyer, Rebecca Driessen and Ella Thompson (VFCTG); The CONSIT TEAM - Monica Barile and Irene Ferce of the Istituto Europeo di Oncologia, Milan, Italy; Gabriele Capone of the University of Florence, Florence, Italy; Alessandra Viel and Riccardo Dolcetti of the CRO Aviano National Cancer Institute, Aviano (PN), Italy; Liliana Varesco of the IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa; Maria Grazia Tibiletti of the Ospedale di Circolo-Università dell’Insubria, Varese, Italy; Antonella Savarese and Aline Martayan of the Istituto Nazionale Tumori Regina Elena, Rome, Italy; Stefania Tommasi and Brunella Pilato of the Istituto Nazionale Tumori "Giovanni Paolo II", Bari, Italy; and the personnel of the Cogentech Cancer Genetic Test Laboratory, Milan, Italy.

We thank members and participants of the following registries: New York Breast Cancer Family Registry (BCFR-NY); Ontario Familial Breast Cancer Registry (BCFR-ON); Netherlands Cancer Registry and PALGA (Dutch Pathology Registry) (HEBON); Hong Kong Hereditary Breast Cancer Family Registry (HRBCP).

Finally we thank the following institutions, organizations and networks for their support: The University of Kansas Cancer Center and Kansas Bioscience Authority Eminent Scholar Program (FCCC); Comprehensive Cancer Centre Netherlands and
Comprehensive Centre South (HEBON); National Cancer Genetics Network «UNICANCER Genetic Group», France (GEMO); Ontario Cancer Genetics Network (OCGN); the Victorian Cancer Registry and the Australian Institute of Health and Welfare including the National Death Index and the Australian Cancer Database (MCCS); Australia New Zealand NRG Oncology group; OSU Human Genetics Sample Bank (OSUCCG); Meirav Comprehensive breast cancer center team at the Sheba Medical Center (SMC-CIMBA); Hong Kong Sanatorium and Hospital (HRBCP); Oncogenetics Group (VHIO); the High Risk and Cancer Prevention Unit of the University Hospital Vall d’Hebron (HVH) and the Cellex Foundation.

CIMBA Funding

The CIMBA database is funded by Cancer Research UK (C12292/A20861 and C12292/A11174). Curation of CIMBA variant nomenclature and classification in the Spurdle lab was supported by funding from the Cancer Council Queensland (APP1086286). A.C.A. is a CRUK Senior Cancer Research Fellow. G.C.T. is an NHMRC Senior Principal Research Fellow. A.B.S. is an NHMRC Senior Research Fellow (APP1061779). A.K.G. was funded by 5U01CA113916, R01CA140323, and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship. B.Poppe is a senior clinical investigator of FWO and M.V.H. obtained funding from IWT (G-FAST). O.I.O. is an ACS Clinical Research Professor. M.H.G. and P.L.M. are supported by the NIH Intramural Research Program of the US National Cancer Institute. B.Y.K. is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN). J.S. is Chairholder of the Canada Research Chair in Oncogenetics; Cancer Association of South Africa to Elizabeth J. van Rensburg (BMBSA). S.L.N. was partially supported by the Morris and Horowitz Families Endowed Professorship (BRICOH). C.I. received support from the Non-Therapeutic Subject Registry Shared Resource at Georgetown University (NIH/NCI P30-CA051008), the Fisher Center for Familial Cancer Research, and Swing For the Cure (GEORGETOWN). J. Lecarpentier has been financially supported by the Fondation ARC (SAE20131200623). D.G.E. is an NIHR Senior Investigator. F.L. is supported by an NIHR grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Elizabeth Bancroft is supported by Cancer Research UK (C5047/A8385). R.E. is supported by CRUK (C5047/A8385).

Funding for individual studies is listed below.

BCFR: NIH (UM1 CA164920)
BFBOCC-LT: Research Council of Lithuania (SEN-18/2015)
BIDMC: U.S. Breast Cancer Research Foundation
CNIO: Spanish Association against Cancer (AECC08), RTICC (06/0020/1060, FISPI08/1120), Mutua Madrileña Foundation, SAF2010-20493 COH-CGCRN.
COH: NIH (RC4CA153828)
CONSIT TEAM: Funds from Italian citizens who allocated the 5x1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws; FiorGen Foundation for Pharmacogenomics.
Identification of twelve new susceptibility loci for different histotypes of epithelial ovarian cancer

Supplementary Note

DEMOKRITOS: European Social Fund; Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (SYN11_10_19 NBCA)

EMBRACE: Cancer Research UK Grants (C1287/A10118 and C1287/A11990).

FPGMX: FISPI05/2275 and Mutua Madrileña Foundation

FCCC: NIH (P30CA168524)

GC-HBOC: German Cancer Aid (110837)

GEMO: the Ligue Nationale Contre le Cancer; the Association “Le cancer du sein, parlons-en!” Award; the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program and the French National Institute of Cancer.

HCSC: ISCIII (RD12/0036/0006 and 12/00539); European Regional Development FEDER funds

HEBCS: Helsinki University Hospital Research Fund, Academy of Finland (266528); the Finnish Cancer Society; the Sigrid Juselius Foundation

HEBON: Dutch Cancer Society (NKI1998-1854, NKI2004-3088, NKI2007-3756), the Netherlands Organization of Scientific Research (NWO 91109024), the Pink Ribbon (110005 and 2014-187); the BBMRI (NWO 184.021.007/CP46); Transcan (JTC 2012 Cancer 12-054).

HRBCP: The Dr. Ellen Li Charitable Foundation

HUNBOCS: Hungarian Research (KTIK-OTKA CK-80745,OTKA K-112228)


IHCC: Grant PBZ_KBN_122/P05/2004

ILUH: Icelandic Association “Walking for Breast Cancer Research”; the Landspitali University Hospital Research Fund.

INHERIT: ‘CIHR Team in Familial Risks of Breast Cancer’ program and the Canadian Breast Cancer Research Alliance (019511)

IOVHBOS: Ministero della Salute and “5x1000” Istituto Oncologico Veneto grant

IPOBCS: Liga Portuguesa Contra o Cancro

KOHBRA: Korean National R&D Program for Cancer Control (1020350)

kConFab: the National Breast Cancer Foundation, National Health and Medical Research Council of Australia the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia; and the Cancer Foundation of Western Australia.

KUMC: NIH (P30CA168524); The University of Kansas Cancer Center

MAYO: David F. and Margaret T. Grohne Family Foundation; NIH (R01CA116167, R01CA128978, R01CA176785, R01 CA116201); U.S. Breast Cancer Research Foundation

MCGILL: Jewish General Hospital Weekend to End Breast Cancer; Quebec Ministry of Economic Development, Innovation and Export

MCCS: VicHealth and Cancer Council Victoria; NHMRC (209057, 251553 and 504711)
Identification of twelve new susceptibility loci for different histotypes of epithelial ovarian cancer

Supplementary Note

MSKCC: Robert and Kate Niehaus Clinical Cancer Genetics Initiative; the Andrew Sabin Research Fund; U.S. Breast Cancer Research Foundation

MODSQUAD: MH CZ - DRO (MMCI, 00209805); European Regional Development Fund; the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101); Charles University in Prague (UNCE204024)

NICCC: Clalit Health Services in Israel; Israel Cancer Association; U.S. Breast Cancer Research Foundation.

NNPIO: Russian Federation for Basic Research (14-04-93959, 15-04-01744)

NRG Oncology: NIH (CA27469, CA37517, CA101165)

NCI: NIH (NO2-CP-11019-50, N02-CP-65504)

OSUCCG: Ohio State University Comprehensive Cancer Center

PBCS: Istituto Toscano Tumori (2011-2013)

SEABASS; Malaysian Ministry of Science, Technology and Innovation, Ministry of Higher Education (UM.C/HIR/UMOHE/06) and Cancer Research Initiatives Foundation

SMC-CIMBA: Israel cancer association; Israeli Inherited breast cancer consortium

SWE-BRCA: Swedish Cancer Society

UCHICAGO: NIH (CA125183, R01CA142996, 1U01CA161032); Ralph and Marion Falk Medical Research Trust; the Entertainment Industry Fund National Women's Cancer Research Alliance; U.S. Breast Cancer Research Foundation

UCLA: UCLA: Jonsson Comprehensive Cancer Center Foundation; U.S. Breast Cancer Research Foundation

UPENN: Susan G. Komen Foundation for the Cure, Basser Research Center for BRCA; U.S. Breast Cancer Research Foundation

UCSF: UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center

UKFOCR: Cancer Research UK

UPITT/MWH: Frieda G. and Saul F. Shapira BRCA-Associated Cancer Research Program; Hackers for Hope Pittsburgh


WCP: NIH (UL1TR000124).